Liposomal drug delivery system as an effective treatment approach for lung cancer
Worldwide, cancer is one of the leading causes of mortality and cancer rates are set to increase at alarming rate globally. There are various types of cancer in which the leading type is the lung cancer. In recent years lipid-based carriers, such as liposomes, have successfully encapsulated chemotherapeutic agents ameliorating some toxicity issues, while enhancing the overall therapeutic activity in cancer patients. In addition to this, nanomaterials can help to improved half-life in the body, morphology, for increased drug loading and many other ways. The survey discussed in this review will lead the anticancer therapy and cancer management which will provide the platform to the next generation. Therefore, this critical review includes the therapeutic interventions, liposomes target delivery, active and passive drug loading. Finally, we attempt to summarize the current challenges in nanotherapeutics and provide an outlook on the future of this important field.
Keywords: Drug Delivery, Liposomes target Delivery, Nanostructures, Drug loading
2. Winterhalter M, Lasic DD. Liposome stability and formation: experimental parameters and theories on the size distribution. Chemistry and physics of lipids. 1993;64(1-3):35-43.
3. Patel J, Amrutiya J, Bhatt P, Javia A, Jain M, Misra A. Targeted delivery of monoclonal antibody conjugated docetaxel loaded PLGA nanoparticles into EGFR overexpressed lung tumour cells. Journal of microencapsulation. 2018;35(2):204-17.
4. Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. Journal of molecular biology. 1965;13(1):238-52.
5. Olson F, Hunt CA, Szoka FC, Vail WJ, Papahadjopoulos D. Preparation of liposomes of defined size distribution by extrusion through polycarbonate membranes. Biochimica et biophysica acta. 1979;557(1):9-23.
6. Szoka F, Jacobson K, Derzko Z, Papahadjopoulos D. Fluorescence studies on the mechanism of liposome-cell interactions in vitro. Biochimica et biophysica acta. 1980;600(1):1-18.
7. Madden TD. Chapter 1 Model membrane systems. In: Bittar EE, Bittar N, editors. Principles of Medical Biology. 7: Elsevier; 1997. p. 1-17.
8. Bhatt P, Lalani R, Vhora I, Patil S, Amrutiya J, Misra A, et al. Liposomes encapsulating native and cyclodextrin enclosed paclitaxel: Enhanced loading efficiency and its pharmacokinetic evaluation. International journal of pharmaceutics. 2018; 536(1):95-107.
9. Mayer LD, Bally MB, Hope MJ, Cullis PR. Uptake of antineoplastic agents into large unilamellar vesicles in response to a membrane potential. Biochimica et biophysica acta. 1985;816(2):294-302.
10. Gabizon A, Goren D, Fuks Z, Meshorer A, Barenholz Y. Superior therapeutic activity of liposome-associated adriamycin in a murine metastatic tumour model. Br J Cancer. 1985;51(5):681-9.
11. Dean RT. Lysosomes and membrane recycling. A hypothesis. Biochemical Journal. 1977;168(3):603-5.
12. Jain MK, Zakim D. The spontaneous incorporation of proteins into preformed bilayers. Biochimica et biophysica acta. 1987;906(1):33-68.
13. Forssen EA, Tökès ZA. Use of anionic liposomes for the reduction of chronic doxorubicin-induced cardiotoxicity. Proceedings of the National Academy of Sciences of the United States of America. 1981;78(3):1873-7.
14. Bhatt P, Vhora I, Patil S, Amrutiya J, Bhattacharya C, Misra A, et al. Role of antibodies in diagnosis and treatment of ovarian cancer: Basic approach and clinical status. Journal of controlled release : official journal of the Controlled Release Society. 2016;226:148-67.
15. Akbarzadeh A, Rezaei-Sadabady R, Davaran S, Joo SW, Zarghami N, Hanifehpour Y, et al. Liposome: classification, preparation, and applications. Nanoscale Res Lett. 2013;8(1):102-.
16. Vyas SP, Sihorkar V, Mishra V. Controlled and targeted drug delivery strategies towards intraperiodontal pocket diseases. Journal of clinical pharmacy and therapeutics. 2000;25(1):21-42.
17. Mishra PK, Gulbake A, Jain A, Vyas SP, Jain SK. Targeted delivery of an anti-cancer agent via steroid coupled liposomes. Drug delivery. 2009;16(8):437-47.
18. Patel P, Hanini A, Shah A, Patel D, Patel S, Bhatt P, Pathak YV. Surface Modification of Nanoparticles for Targeted Drug Delivery. In Surface Modification of Nanoparticles for Targeted Drug Delivery ,Cham: Springer International Publishing. 2019:19-31.
19. Lalani RA, Bhatt P, Rathi M, Misra A. Abstract 2063: Improved sensitivity and in vitro efficacy of RGD grafted PEGylated gemcitabine liposomes in RRM1 siRNA pretreated cancer cells. Cancer Research. 2016;76(14 Supplement):2063.
20. Tripathi D, Therapondos G, Lui HF, Johnston N, Webb DJ, Hayes PC. Chronic Administration of Losartan, an Angiotensin II Receptor Antagonist, is not Effective in Reducing Portal Pressure in Patients with Preascitic Cirrhosis. American Journal of Gastroenterology. 2004;99(2).
21. Tannock IF, Warr DG. Unconventional therapies for cancer: a refuge from the rules of evidence? CMAJ : Canadian Medical Association journal de l'Association medicale canadienne. 1998;159(7):801-2.
22. Tannock IF. Conventional cancer therapy: promise broken or promise delayed? Lancet (London, England). 1998;351 Suppl 2:Sii9-16.
23. Jang SH, Wientjes MG, Lu D, Au JL. Drug delivery and transport to solid tumors. Pharmaceutical research. 2003;20(9):1337-50.
24. Baxter LT, Jain RK. Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection. Microvascular Research. 1989;37(1):77-104.
25. Doyle L, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene. 2003;22(47):7340-58.
26. Molema G. Tumor vasculature directed drug targeting: applying new technologies and knowledge to the development of clinically relevant therapies. Pharmaceutical research. 2002;19(9):1251-8.
27. Carmeliet P. Angiogenesis in health and disease. Nature medicine. 2003;9(6):653-60.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).